[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371307-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371307-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cnv-mediated-dysregulation-of-the-cerna-network-mechanism-revealed-heterogeneity-in-diffuse-and-intestinal-gastric-cancers","CNV-mediated dysregulation of the ceRNA network mechanism revealed heterogeneity in diffuse and intestinal gastric cancers","","Gastric cancer is a highly heterogeneous disease, with diffuse and intestinal subtypes showing distinct pathophysiological and molecular features. This study identifies driver genes linked to subtype differences by analyzing copy number variation (CNV) genes within the competing endogenous RNA (ceRNA) network. The driver CNV genes explain molecular, cellular, and clinical divergence through effects on the tumour microenvironment. Results highlight subtype-specific therapeutic opportunities and propose personalized strategies, including immune checkpoint inhibition for intestinal cancer and tailored options for diffuse cancer patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cnv-mediated-dysregulation-of-the-cerna-network-mechanism-revealed-heterogeneity-in-diffuse-and-intestinal-gastric-cancers/371307/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cnv-mediated-dysregulation-of-the-cerna-network-mechanism-revealed-heterogeneity-in-diffuse-and-intestinal-gastric-cancers/371307.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of this study on gastric cancer subtypes?","Question",{"text":63,"@type":64},"To identify driver genes associated with diffuse and intestinal gastric cancers by examining CNV genes within the ceRNA network and linking them to subtype-specific differences.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were driver genes connected to subtype heterogeneity?",{"text":68,"@type":64},"By analyzing how driver CNV genes influence molecular, cellular, and clinical differences between diffuse and intestinal gastric cancers through the ceRNA network and associated changes in the tumour microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment implications does the study suggest?",{"text":72,"@type":64},"Immune checkpoint inhibitors may be effective for intestinal gastric cancer, while diffuse gastric cancer may benefit from adjuvant chemotherapy when PPIF has homozygous deletion and from targeted therapy when MTAP is highly amplified.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371307,1791131621,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Xu etal. Journal of Translational Medicine (2025) 23:308  \n[https://doi.org/10.1186/s12967-025-06222-x](https://doi.org/10.1186/s12967-025-06222-x)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nCNV-mediated dysregulation of the ceRNA   network mechanism revealed heterogeneity in diffuse and intestinal gastric cancers  \nRongji Xu1†, Danni He1†, Rui Sun1†, Jiaqi Zhou2†, Mengyu Xin1, Qian Liu1, Yifan Dai1, Houxing Li1, Yujie Zhang1, Jiatong Li1, XinXin Shan1, Yuting He1, Borui Xu1, Qiuyan Guo3, Shangwei Ning1*, Yue Gao1* and Peng Wang1*  \nAbstract  \nBackground Gastric cancer (GC) is a highly heterogeneous tumour with high morbidity. Approximately 95% of GC cases are gastric adenocarcinomas, which are further categorized into two predominant subtypes: diffuse gastric cancer (DGC) and intestinal gastric cancer (IGC) . These subtypes exhibit distinct pathophysiological and molecular characteristics, reflecting their unique tumorigenic mechanisms.  \nMethod In this study, we employed a comprehensive approach to identify driver genes associated with DGC and IGC by focusing on copy number variation (CNV) genes within the competing endogenous RNA (ceRNA) network. The influence of driver CNV genes on the molecular, cellular, and clinical differences between DGC and IGC was subsequently analysed. Finally, therapeutic strategies for DGC and IGC were evaluated based on the status and functional pathways of the driver CNV genes.  \nResults A total of 17 and 22 driver CNV genes were identified in DGC and IGC, respectively. These genes drive subtype differences through the ceRNA network, resulting in alterations in the tumour microenvironment (TME) . Based on these differences, personalized treatment strategies for DGC or IGC could be developed. Immune checkpoint inhibitors maybe an effective treatment option in IGC. Additionally, DGC patients with homozygous deletion of PPIF might benefit from adjuvant chemotherapy, whereas those with high-level amplification of MTAP could respond to targeted therapy. Conclusion Driver CNV genes were identified to reveal the underlying cause of heterogeneity in DGC and IGC. Furthermore, specific driver CNV genes were identified as potential therapeutic targets, facilitating personalized treatment.  \nKeywords Diffuse gastric cancer, Intestinal gastric cancer, CNV, CeRNA, Driver genes, Tumour heterogeneity  \n†Rongji Xu, Danni He, Rui Sun and Jiaqi Zhou these authors wish it to be known that, in their opinion, the first four authors should be regarded as joint First Authors.  \n*Correspondence: Shangwei Ning [ningsw@ems.hrbmu.edu.cn](ningsw@ems.hrbmu.edu.cn)[ ](ningsw@ems.hrbmu.edu.cn)Yue Gao [gaoyue_hrm@163.com](gaoyue_hrm@163.com)[ ](gaoyue_hrm@163.com)Peng Wang [wpgqy@hrbmu.edu.cn](wpgqy@hrbmu.edu.cn)  \n1 College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China  \n2 The First Clinical School of Gansu University of Chinese Medicine, Lanzhou 730030, China  \n3 The First Affiliated Hospital of Harbin Medical University, Harbin 150081, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from th","cbCainDKrCVAJ55x","https://ap.wps.com/l/cbCainDKrCVAJ55x","pdf",6861646,16,"English","# Abstract\n# Background\n# Method\n# Results\n# Conclusion\n# Introduction\n## Gastric cancer heterogeneity and subtype features\n## Role of ceRNA and CNV in molecular interactions","[{\"question\":\"What is the main goal of this study on gastric cancer subtypes?\",\"answer\":\"To identify driver genes associated with diffuse and intestinal gastric cancers by examining CNV genes within the ceRNA network and linking them to subtype-specific differences.\"},{\"question\":\"How were driver genes connected to subtype heterogeneity?\",\"answer\":\"By analyzing how driver CNV genes influence molecular, cellular, and clinical differences between diffuse and intestinal gastric cancers through the ceRNA network and associated changes in the tumour microenvironment.\"},{\"question\":\"What treatment implications does the study suggest?\",\"answer\":\"Immune checkpoint inhibitors may be effective for intestinal gastric cancer, while diffuse gastric cancer may benefit from adjuvant chemotherapy when PPIF has homozygous deletion and from targeted therapy when MTAP is highly amplified.\"}]","CNV-mediated dysregulation of the ceRNA network mechanism revealed heterogeneity in diffuse and intestinal gastric cancers | PDF",1790191762,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20c51e85852ea79a05083473b1707908.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd4bfac346236f4308c099d6219d26a7.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e606b66a4be08abd01fdf8bd49f00d0.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a176bc2758ed84691e9c68a883170b2a.webp",980,1301]